Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 3/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5823535 | 0.89 | GCGR (0.71) | GCGRMAPK14HPGDALDH1A1 | |
| SCHEMBL8498146 | 0.89 | GCGR (0.57) | GCGRMAPK14HPGDALDH1A1KDM4E | |
| SCHEMBL5311606 | 0.82 | CA2 (0.54) | — | |
| SCHEMBL6195404 | 0.82 | SMN1; SMN2 (0.47) | GCGRMAPK14HPGDALDH1A1KDM4E | |
| SCHEMBL3504485 | 0.80 | PDE3B (0.56) | HPGDALDH1A1KDM4ESMN1; SMN2PDE4A | |
| SCHEMBL17054242 | 0.80 | HPGDS (0.46) | HPGDALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL30726109 | 0.79 | GCGR (0.56) | GCGRMAPK14SMN1; SMN2 | |
| SCHEMBL6960951 | 0.77 | PDE4A (0.44) | HPGDALDH1A1KDM4ESMN1; SMN2PDE4A | |
| SCHEMBL14028213 | 0.76 | PDE4A (0.49) | HPGDALDH1A1KDM4ESMN1; SMN2PDE4A | |
| SCHEMBL7983759 | 0.76 | GCGR (0.53) | GCGRMAPK14SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106866484-B | A method of preparing pyrroles, imidazoles, oxazole derivatives | 中国科学院大连化学物理研究所 | 2019-04-09 | — | — | CN | disclosed |
| US-8044072-B2 | Pyrrole derivatives, preparation thereof and therapeutic use thereof | SANOFI AVENTIS (FR) | 2011-10-25 | — | — | US | disclosed |
| US-7879902-B2 | Psychological disorders; eating disorders; metabolism disorders; cognition activators; alcoholism; drug abruse thereapy | SANOFI-AVENTIS (FR) | 2011-02-01 | — | — | US | disclosed |
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20090281116-A1 | PYRROLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-11-12 | — | — | US | disclosed |
| US-20080194581-A1 | PYRROLE DERIVATIVES, INTERMEDIATES THEREFOR, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-08-14 | — | — | US | disclosed |
| US-7381727-B2 | Pyrrole derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2008-06-03 | — | — | US | disclosed |
| US-20070149596-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-06-28 | — | — | US | disclosed |
| US-5260451-A | Enzyme inhibitors | MERCKLE GMBH (DE) | 1993-11-09 | — | — | US | disclosed |
| EP-0397175-A1 | Substituted pyrrolizine compounds and theit use as pharmaceuticals | Dannhardt, Gerd, Prof.Dr. (DE) | 1990-11-14 | — | — | EP | disclosed |
| US-4477463-A | Antiinflammatory and/or analgesic 1-alkyl-4,5-diaryl-2-fluoroalkyl-1H-pyrroles | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-10-16 | — | — | US | disclosed |
| US-4318917-A | PREPARED FROM A PYRROLE COMPOUND AND A 1-3-DITHIETANE COMPOUND | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-03-09 | — | — | US | disclosed |
| EP-0044485-A1 | Antiinflammatory 2,3-diaryl-5(2,2,2-trifluoro-1-(trifluoromethyl)-ethyl)-1H-pyrroles | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194581-A1 | PYRROLE DERIVATIVES, INTERMEDIATES THEREFOR, PREPARATION AND THERAPEUTIC USE THEREOF | PYCR1, FARS2, WEE1 | GCGR 2257/4885MAPK14 3172/4885HPGD 240/4885 |
| US-20070149596-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | PYCR1, PRMT9, PRLHR | GCGR 1580/4885MAPK14 4764/4885HPGD 732/4885 |
| US-20090281116-A1 | PYRROLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | PRMT9, PYCR1, EPOR | GCGR 1912/4885MAPK14 4739/4885HPGD 444/4885 |
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | UROD, UTS2R, SLC14A1 | GCGR 4082/4885MAPK14 985/4885HPGD 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.